医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

New white paper from International SOS & Enhesa; Operating in China: Mitigating Human Capital Risks and Occupational Health Challenges in China

2019年10月29日 PM10:53
このエントリーをはてなブックマークに追加


 

SHANGHAI

As an economic leader in growth, China has become an attractive country for international and regional organisations looking to set up operations. However, when complying with new health and safety regulations, a business can face a number of new challenges. To protect its 776 million strong workforce, there has been a shift in the regulatory structure on occupational health and compliance in China. It is now imperative for organisations currently operating, or looking to operate in the country, to implement clear policies and procedures in order to avoid financial and legal implications.

To help organisations gain insight into the occupational health risks and requirements of operating in China, International SOS has partnered with Enhesa, to produce a new white paper: Operating in China Mitigating Human Capital Risks and Occupational Health Challenges in China. The paper addresses aspects including The Belt and Road Initiative (BRI) and the impact of non-communicable diseases, as well as initiatives like the ‘Healthy China 2030 Planning Outline.’

Dr Vincent Yue, Regional Medical Director at International SOS, comments, “As the world’s second largest economy, the business opportunities in China are rife. In order to maximise these opportunities, it is imperative that employers understand the moral and legal obligations to provide Duty of Care to employees. Healthcare is central to the Chinese government’s agenda, but the medical practice infrastructure and medical management system is different to that of the west. This paper provides guidance as well as recommended best practice for organisations to protect their workforce and business resilience.”

Jessica Sarnowski, Head of Content Marketing & Thought Leadership at Enhesa, comments, “China’s increased emphasis on occupational health protection for employees makes it imperative for employers to be aware of the key pieces of legislation outlined in this whitepaper. Global companies that have a place of business in China should take note, not only of the evolving legal requirements in China, but also the best practices for mitigating risks related to employee health.”

The transformation and reforms of China’s healthcare system is an on-going effort and critical for the domestic agenda for the Chinese government. The strategy of “Health China 2030” highlights the importance of occupational health workplace safety, and goes as far as outlining directions for occupational health practitioners.

To read the full white paper, click here. The white paper will also be available in Mandarin by December 2019.

ENDS

View source version on businesswire.com: https://www.businesswire.com/news/home/20191029005698/en/

CONTACT

Suzanne Withers, Head of Group PR, International SOS

T: +44 (0) 208 762 8494, M: +44 (0)7584 522 497, E: suzanne.withers@internationalsos.com

同じカテゴリーの記事 

  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続